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Abstract: Rho guanosine triphosphatases (GTPases) are key regulators in a number of cellular 
functions, including actin cytoskeleton remodeling and vesicle traffic. Traditionally, Rho GTPases 
are studied because of their function in cell migration and cancer, while their roles in metabolism 
are less documented. However, emerging evidence implicates Rho GTPases as regulators of 
processes of crucial importance for maintaining metabolic homeostasis. Thus, the time is now ripe 
for reviewing Rho GTPases in the context of metabolic health. Rho GTPase-mediated key processes 
include the release of insulin from pancreatic β cells, glucose uptake into skeletal muscle and 
adipose tissue, and muscle mass regulation. Through the current review, we cast light on the 
important roles of Rho GTPases in skeletal muscle, adipose tissue, and the pancreas and discuss the 
proposed mechanisms by which Rho GTPases act to regulate glucose metabolism in health and 
disease. We also describe challenges and goals for future research. 
Keywords: Rho GTPases; metabolism; glucose homeostasis; GLUT4 translocation; skeletal muscle; 
pancreas; insulin; diabetes; ageing 
 
1. Introduction 
The Rho family of small guanosine triphosphatases (GTPases) is a distinct branch within the 
superfamily of Ras-related small GTPases. Twenty mammalian genes encoding Rho GTPases have 
been identified of which Rac1, Cdc42, and RhoA are the prototypes and therefore the best 
characterized. Rho GTPases are crucial organizers of the actin cytoskeleton with essential functions 
in cell migration, cell–cell contacts, proliferation, differentiation, and many other fundamental 
cellular processes [1,2]. Not surprisingly, this family of molecules plays central roles in maintenance 
of health and their dysregulation often results in disease [3]. In the last few years, important and 
often surprising insight into the in vivo functions of Rho GTPases has been gained. An essential 
function of Rho GTPases, only recently elucidated, is the regulation of processes important for the 
maintenance of whole body metabolic homeostasis, in particularly glucose metabolism and blood 
glucose control via their actions in metabolically active tissues, such as skeletal muscle and adipose 
tissue, as well as the pancreas. 
Today metabolic diseases significantly contribute to early death in Western society. More than 
422 million people worldwide are estimated to have diabetes causing 3% of global deaths [4]. 
Metabolic diseases also contribute to 1/3 of all cancers [5] and cancer-related deaths [6]. Type 2 
diabetes is a metabolic disease that is associated with obesity, reduced insulin-stimulated glucose 
uptake by skeletal muscle and adipose tissue, and impaired β cell function [7]. Because of their 
important roles in those processes, Rho GTPases represent a hitherto understudied potential for 
novel ways to understand dysfunctions in metabolic disease. This review will discuss the key 
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evidence for the role of Rho GTPases in metabolic control and delineate the underlying molecular 
mechanisms. Further, this is extrapolated to discuss the role of Rho GTPases in conditions of 
metabolic dysfunction, such as type 2 diabetes and ageing. 
1.1. Mechanisms of Action 
1.1.1. General Mechanisms of Activation 
Wide interest in small GTPases was triggered by the discovery of the Ras oncogenes in 1982 [8] 
and with its mutations a few years later proven to cause human cancers [9,10]. Those discoveries 
were soon followed by the identification of related proteins now forming the Ras superfamily 
[11,12]. Rho GTPases function as molecular switches that cycle between an inactive guanosine 
diphosphate (GDP)-bound and an active guanosine triphosphate (GTP)-bound state (Figure 1). At 
least three major types of regulatory proteins/factors are described for Rho GTPases as illustrated in 
Figure 1. Activation of Rho GTPases is induced by guanine nucleotide exchange factors (GEFs), 
which facilitate switching from a GDP- to a GTP-bound state. Inactivation results from 
GTPase-activating proteins (GAPs) that promote the intrinsic GTPase activity mediating GTP to 
GDP hydrolysis [13,14]. Additionally, Rho guanine dissociation inhibitors (RhoGDIs) bind to the 
inactive, GDP-bound form of Rho GTPases maintaining their inactive state [15,16]. Thus, in order for 
a biological event to activate Rho GTPases, the balance between the GEFs, GAPs, and RhoGDIs must 
be altered to promote the Rho GTPase GTP-bound state. Mammalian cells encode genes for 
numerous of GEFs (>80) and GAPs (>60), but only three RhoGDIs [17]. Depending on the biological 
mode of regulation, release from RhoGDI must occur and GEFs must be activated to interact with 
the Rho GTPase and promote GTP binding. Conversely, inactivation occurs when GAPs promote the 
GTP hydrolysis. Rho GTPases can then be extracted from the membrane by RhoGDIs. 
 
Figure 1. Rho guanosine triphosphatase (GTPase) nucleotide cycle. Activation of Rho GTPases 
require: i) release from Rho guanine dissociation inhibitors (GDIs) and ii) activation of guanine 
nucleotide exchange factors (GEFs), which facilitate switching from an inactive guanosine 
diphosphate (GDP)-bound to an active guanosine triphosphate (GTP)-bound state and translocation 
to the plasma membrane. Inactivation occurs when GTPase-activating proteins (GAPs) stimulate 
GTP to GDP hydrolysis and the Rho GTPase re-binds to RhoGDI. Free prenylated Rho GTPases are 
unstable and degraded and also active Rho GTPases can be targeted to degradation. 
In addition to the regulation of the GTP–GDP cycling, post-translational modifications (e.g., 
isoprenylation, palmitoylation, phosphorylation, ubiquitination, sumoylation) of Rho GTPases 
appear to be additionally required for optimal regulation of Rho GTPase function [18,19]. The 
intracellular spatiotemporal distribution of Rho GTPases is tightly controlled. In general, active Rho 
GTPases are targeted to the plasma membrane (or endosomal membranes) via a polybasic region 
and a prenyl group attached to a C-terminal cysteine residue, and several Rho GTPases are also 
palmitoylated [18,20,21]. Prenylated cytosolic Rho GTPases are unstable and rapidly degraded [22]. 
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Additionally, active Rho GTPases can be targeted for proteasomal degradation by ubiquitination 
[19,23]. The molecular chaperone, RhoGDI, binds to prenylated Rho GTPases forming a cytosolic 
pool of mainly inactive GDP-loaded Rho GTPases and protects Rho GTPases from ubiquitination 
and degradation [22]. Thus, while release from RhoGDI is a necessary event for the Rho GTPases to 
be activated, the release may reduce Rho GTPase protein abundance. Like Rho GTPases, GEFs, 
GAPs, and RhoGDIs are also regulated by post-translational modifications, revealing the many 
modalities for regulation of these key molecular switches [19]. Yet another layer of complexity is 
added to the regulation of the spatiotemporal distribution and activation, as Rho GTPases can 
interact to regulate each other’s activity. For example, the Rho GTPases, Rac1/Cdc42, and RhoA have 
opposing roles and double-negative feedback loops exist between them [24–26]. The mechanisms 
underlying this feedback regulation between Rho GTPases are not resolved but might involve Rho 
GTPase competitive binding to RhoGDI [22]. One study found that in vascular smooth muscle cells, 
phosphorylation of RhoA on S188 induced dissociation of Rac1 from RhoGDIα, thereby activating 
Rac1 and vascular smooth muscle cell migration [27], while protecting RhoA from 
ubiquitin/proteasome-mediated degradation [28]. Moreover, feedback loops exist between 
downstream effector proteins and the Rho GTPases. The downstream effectors of Rac1/Cdc42, 
p21-activated kinases (PAKs), have been reported to negatively regulate GEFs [29,30], while PAK1 
phosphorylation of RhoGDI at site S101 and S174 leads to RhoGDI dissociation from Rac1 [31]. 
Additionally, pharmacological inhibition (IPA-3) of PAK1-3 lowered Rac1 activity [24]. This also 
increased RhoA activity in agreement with the above mentioned negative regulation between the 
Rho GTPases. 
As outlined above, the regulation of Rho GTPases is highly complex making it challenging to 
determine the exact regulatory mechanisms operating under any one circumstance.  
1.1.2. Downstream Effects 
Active Rho GTPases recruit downstream effector molecules to the plasma membrane and 
trigger their activation [32]. Conserved structure and mechanism in multiple versions of Rho 
GTPases in bacteria, yeast, flies, and vertebrates, suggest that all derive from a single primordial 
protein, repeatedly modified in the course of evolution to perform a variety of functions. Each Rho 
GTPase affects numerous downstream proteins, all of which have specific roles in various cell 
processes [32,33]. Especially Rac1, Cdc42, and RhoA control pathways central to metabolic 
regulation. Rho GTPases are crucial organizers of the actin cytoskeleton (Figure 2). Active 
GTP-bound RhoA, Rac1, and Cdc42 promote the assembly of actin stress fibers and focal adhesions, 
thin sheet-like lamellipodial protrusions and finger-like filopodial protrusions, respectively [34–39]. 
The regulation of the actin cytoskeleton by Rho GTPases are extensively reviewed in [1,40,41] and 
only selected regulatory mechanisms investigated in relation to metabolic regulation will be 
presented here. 
Actin remodeling is controlled through parallel actin polymerization and depolymerization. 
Generally, Rac1 and Cdc42 regulate comparable downstream events via activation of PAKs and 
activation of the Wiskott–Aldrich syndrome family of proteins including Wiskott-Aldrich Syndrome 
protein (WASP), neural-WASP (N-WASP), and WASP family verprolin homologous protein 1 or 2 
(WAVE1/2). WASP and N-WASP are critical downstream effectors of Cdc42 that mediate the 
formation of filopodia through activation of the actin polymerization factor Arp2/3 [42]. Likewise, 
Rac1 exerts its effect on the cytoskeleton by binding to the WAVE complex, releasing WAVE and 
thereby promoting lamellipodia polymerization via activation of the Arp2/3 complex [43]. 
Among other downstream effectors, PAKs activate LIM domain kinases (LIMKs) promoting 
phosphorylation and inactivation of cofilin [42]. Active cofilin severs and depolymerizes actin 
filaments and leads to an increase in uncapped barbed ends promoting actin polymerization [42,44]. 
To counteract LIMK-dependent inactivation of cofilin, Rac1 activates the cofilin phosphatase, 
slingshot1 (SSH1). . Thereby, phosphorylation of cofilin is tightly regulated by Rac1 by two opposite 
mechanisms, which results in cofilin dephosphorylation and activation [45–47]. Rac1 is also an 
essential component for the assembly of the NADPH oxidase complex (NOX2) by binding to 
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p67-phox, and thereby facilitates the production of reactive oxygen species (ROS) at cell membranes 
[48,49]. 
Critical downstream effectors of RhoA are Rho-associated protein kinase (ROCK) and the 
Formin family of proteins that promotes the formation of straight, unbranched actin fibers. ROCK 
phosphorylates a large cohort of actin-binding proteins and intermediate filament proteins to 
modulate their functions. For example, ROCK phosphorylates LIMK leading to the phosphorylation 
and inactivation of the actin severing protein cofilin [50,51]. Formins capable of actin nucleation 
promote the elongation of pre-existing filaments by removing barbed end capping proteins [52]. 
Diaphanous formin (mDIa) is the most extensively studied and suggested to regulate microtubule 
stabilization in addition to its actin polymerization activity [53,54]. 
Whereas both downstream pathways of Rac1 and Cdc42 seem to be involved in metabolic 
control, RhoA may via downstream effectors be involved in muscle mass regulation and thereby 
play an important role in conditions of muscle mass loss. This will be reviewed below with emphasis 
on knowledge gained from in vivo studies and humans. 
 
Figure 2. Downstream effector proteins of the major Rho GTPases, Rac1, Cdc42, and RhoA. 
Downstream effector proteins of Rac1 and Cdc42 include the Wiskott–Aldrich syndrome family of 
proteins (Wiskott-Aldrich Syndrome protein (WASP), neural-WASP (N-WASP), WASP family 
verprolin homologous protein 1 or 2 (WAVE1/2)) and p21-activated kinases (PAKs). WASP, 
N-WASP, and WAVE promote actin polymerization via activation of the Arp2/3 complex. PAKs 
activate LIM domain kinases (LIMKs) promoting phosphorylation and inactivation of the actin 
severing protein cofilin. Rac1-dependent activation of slingshot1 (SSH1) promotes cofilin 
dephosphorylation and actin depolymerization (actin turnover). Downstream effector proteins of 
Rac1 also include the NADPH oxidase complex (NOX2) to produce reactive oxygen species (ROS) at 
the cellular membrane. Downstream effector proteins of RhoA include Rho-associated protein kinase 
(ROCK) and the formin family of proteins (mDia). Among other downstream effector proteins, 
ROCK regulates the actin turnover via the LIMK–Cofilin pathway. 
Cells 2019, 8, 434 5 of 21 
 
2. Rho GTPases in Regulation of Glucose Homeostasis 
Rho GTPases have important functions during cell development and differentiation (reviewed 
in [1,55–57]). They also play crucial roles in fully differentiated tissues, including the pancreas, 
skeletal muscle, and adipose tissue (Figure 3). Following a meal, nutrients are absorbed in the 
intestines and enter the circulation. This results in a postprandial transient increase in blood glucose 
and free fatty acids. Blood glucose quickly returns to baseline because of an increased secretion of 
the hormone insulin from the pancreatic β cells. When in circulation, insulin stimulates glucose 
uptake into skeletal muscle and the adipose tissue together with inhibition of hepatic glucose 
production. Thereby insulin returns blood glucose back to baseline [58]. Those processes are 
significantly dysregulated in metabolically dysfunctional conditions, such as type 2 diabetes and 
obesity [59–61]. Both the pancreatic release of insulin and resulting insulin-stimulated uptake of 
glucose into skeletal muscle and adipose tissue are tightly regulated by complex processes that 
involve Rho GTPases. Rho GTPases likely also play insulin-independent roles in the maintenance of 
glucose homeostasis, including exercise-stimulated glucose uptake and beneficial adaptations to 
exercise training. In the following sections, we will delineate and discuss the current evidence for a 
role of Rho GTPases with a focus on their roles in maintaining glucose homeostasis. 
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Figure 3. Rho GTPases play tissue-specific crucial roles in fully differentiated tissues, including the 
pancreas, skeletal muscle, and adipose tissue with the main physiological outcome of lowering blood 
glucose. 
2.1.1. Insulin Secretion by Pancreatic β Cells 
The secretion of insulin is an essential everyday event that occurs following a meal to promote 
glucose disposition by the muscle and curb hepatic glucose output. Several lines of evidence place 
Rho GTPases, in particular Cdc42 and Rac1, as important players in glucose-stimulated insulin 
secretion via their roles in actin reorganization [62–65] as depicted in Figure 3. Glucose is a 
hydrophilic molecule that cannot cross the lipid bilayer membrane. High blood glucose is sensed by 
pancreatic β cells and the glucose taken up through GLUcose transporters (GLUTs; predominantly 
GLUT1 and GLUT3 in human islets, GLUT2 in rodents). In general terms, this rapidly translates into 
elevated intracellular ATP, which in turn closes the ATP-sensitive potassium ion channel, leading to 
depolarization of the cell membrane. Depolarization causes the opening of voltage-gated calcium 
channels, and insulin vesicles fuse with the cell membrane to release insulin (reviewed in [66]). 
During the fasting state when levels of blood glucose are low, the actin cytoskeleton restricts the 
access of secretory insulin-containing vesicles to their release sites. In response to a postprandial 
increase of blood glucose, the β cell’s actin cytoskeleton is reorganized, enabling insulin-containing 
vesicle translocation to the plasma membrane. Under normal circumstances, Cdc42 and Rac1 
activation is needed for this process [58,63,67]. The precise mechanisms by which high glucose 
activates Rho GTPases are not clear but in vitro studies have shown that in response to glucose 
stimulation, Cdc42 is activated, which leads to Rac1 activation via PAK1 [68]. In agreement, isolated 
islets from pancreatic β cell-specific Rac1 knockout mice showed decreased glucose-stimulated 
insulin secretion in response to high glucose concentrations [65]. On the other hand, in vitro studies 
show that expression of constitutively active Cdc42 interferes with β cell differentiation leading to 
hyperglycemia [63]. Thus, tight regulation of the Rho GTPases must be in place. In vivo work from 
Thurmond’s group shows that the downstream effector of Cdc42 and Rac1, PAK1, is involved in 
insulin secretion, as whole body PAK1 knockout mice were glucose intolerant due to reduced 
insulin production [69]. 
Overall, it is well established that Rho GTPases play essential roles in normal β cell function and 
insulin secretion, primarily via the essential role of Cdc42 and Rac1 in insulin-vesicle translocation in 
response to increased glucose concentration in the circulation. However, the up- and downstream 
mechanisms remain to be clearly defined. 
2.1.2. Rho GTPases are Implicated in β Cell Dysfunction in Metabolic Disease 
Type 2 diabetes is associated with defects in insulin secretion whereby pancreatic β cells fail to 
compensate for peripheral insulin resistance (described below) so that hyperglycemia ensues [70]. 
Before the onset of type 2 diabetes, insulin resistance causes hyperproduction of insulin to overcome 
the insulin resistance of muscle, adipose tissue, and the liver. Accelerated insulin production is only 
tolerated for a limited period of time, after which the insulin-producing β cells dedifferentiate and 
insulin production is impaired or even stopped [71]. The stage of insulin hyperproduction has been 
associated with conditions of glucotoxicity and accelerated production of reactive oxygen species 
(ROS) in the islets. Rac1 is an important regulator of the assembly of the NADPH oxidase (NOX2) 
complex at the plasma membrane [49]. While ROS production is important for glucose-stimulated 
insulin secretion, uncontrolled Rac1-mediated superoxide hyperproduction is associated with β cell 
failure (reviewed in [72]). For example, hyperactivation of Rac1 has been demonstrable in human 
islets exposed to glucotoxic conditions and in islets derived from the Zucker diabetic fatty (ZDF) rat 
[73], a model of type 2 diabetes. Indeed, suppression of Rac1 activation protects β cells against 
noxious effects of glucolipotoxicity and cytokines [73,74]. Thus, Rac1 exerts damaging roles under 
pathological conditions by inducing NOX2 activity to create excessive oxidative stress, 
mitochondrial damage, and cell death [72,75]. In support of that, the expression and activation of 
Rac1 in pancreatic tissue from ob/ob mice, a model for obesity, is increased [76]. Interestingly, islets 
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from donors with type 2 diabetes display an average PAK1 protein loss of 80% compared with 
non-diabetics [69] and recent work has shown that islets from donors with type 2 diabetes had 
profound defects in glucose-stimulated Cdc42 and PAK1 activation together with impaired 
glucose-stimulated insulin secretion [77]. Long-term hyperglycemia causing glucotoxicity has also 
been linked to RhoA-dependent stress fiber formation and diminished glucose-stimulated insulin 
secretion [78].  
Thus, while the Rho GTPases Cdc42 and Rac1 are critical for insulin secretion, pathological 
hyperactivation of Rac1 and RhoA negatively affects β cell function during times of stress and may 
thus be targets for preventing β cell failure in diabetes. 
2.2. Rho GTPases Regulate Glucose Uptake 
The Rho GTPases Rac1, RhoA, and Cdc42 are highly expressed in skeletal muscle and adipose 
tissue and emerging evidence suggests that they have key functions in the regulation of glucose 
uptake and the maintenance of whole body glucose homeostasis. 
2.2.1. Rho GTPases in Insulin Action in Skeletal Muscle 
In response to insulin, the majority of dietary glucose is taken up by skeletal muscle [79,80]. 
Comprising 40–50% of the body, skeletal muscle is essential for maintaining whole body glucose 
homeostasis. Glucose uptake into skeletal muscle is an actively regulated process that necessitates 
mobilization and insertion of GLUT4 into the plasma membrane. This mechanism is primarily 
promoted by insulin and muscle contraction [81,82]. Perhaps not surprisingly due to their major role 
in vesicle traffic in other cell types, Rho GTPases are involved in the traffic of GLUT4-containing 
vesicles to the muscle plasma membrane (Figure 3). 
Rac1, TC10, and RhoA are activated by insulin in skeletal muscle [83–87]. The first evidence that 
Rho GTPases are actively involved in the regulation of glucose uptake in skeletal muscle came 
nearly 20 years ago when the lack of functional Rac1 was observed to attenuate insulin-stimulated 
GLUT4 translocation in L6 muscle cells in vitro [88,89]. Additionally, constitutive active Rac1, but 
not Cdc42 or TC10, increased the amount of GLUT4 in the plasma membrane [83,90]. Subsequent 
studies also demonstrated an important role for Rac1 in insulin action in mature skeletal muscle in 
vivo. In mouse skeletal muscle, pharmacological inhibition and genetic ablation of Rac1 abolished 
insulin-stimulated GLUT4 translocation and reduced insulin-stimulated glucose uptake 
[86,87,91,92]. 
The involvement of Rac1 in insulin-stimulated GLUT4 translocation has been ascribed to a 
Rac1-mediated insulin-stimulated actin remodeling in skeletal muscle cells [83,88,89]. However, the 
relevance of a mobile actin cytoskeleton in fully mature skeletal muscle was recently questioned as 
mice that lack β-actin, one of the major actin cytoskeleton isoforms in skeletal muscle, displayed 
normal glucose transport [93]. On the other hand, in mature skeletal muscle, the actin 
depolymerizing agent, Latrunculin B reduced insulin-stimulated glucose uptake [87,91], suggesting 
participation of the actin cytoskeleton. 
It is largely unknown how Rho GTPases are activated by insulin but it seems to occur 
downstream of phosphatidylinositol 3-kinase (PI3K). Skeletal muscle evidently expresses the 
following GEFs for Rac1: Tiam1 [94], Trio [95], Def6 [96], son of sevenless [97], Arf6 [98], Kalirin [99], 
Vav2, FLJ00068, DBl-I, α- and β-PIX (PAK-interacting exchange factor)[100], and switch-associated 
protein 70 (SWAP70) [90]. Among these, FLJ00068 has been suggested to regulate insulin-stimulated 
Rac1-dependent GLUT4 translocation in L6 myotubes [90] and mouse skeletal muscle [101]. Further 
research within this area will add to the understanding of the mechanism by which Rac1 regulates 
GLUT4 translocation. 
RhoGDIα and RhoGDIβ are expressed in skeletal muscle [102,103] and RhoGDIα (but not 
RhoGDIβ) forms complexes with Rac1, RhoA, and Cdc42 [15]. Recent data from our laboratory has 
identified RhoGDIα as a negative regulator of Rac1 activity and GLUT4 translocation in skeletal 
muscle. In L6-GLUT4myc myotubes, siRNA-mediated RhoGDIα knockdown augments Rac1 
activity and GLUT4 translocation both in the basal state and in response to insulin stimulation. 
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Corroborating those in vitro results, RhoGDIα overexpression in mouse skeletal muscle in vivo 
decreased insulin-stimulated glucose uptake and impaired whole-body glucose tolerance 
(unpublished work, [104]). Thus, RhoGDIα is a novel key regulator of Rac1, important for 
maintaining the appropriate level of glucose uptake in muscle. The mechanisms by which insulin 
triggers Rac1 dissociation from RhoGDIα in skeletal muscle are currently unknown but it could 
involve phosphorylation of RhoGDIα by PAK or Src as described for other cell types [105,106]. 
Downstream of Rac1, PAK1 and PAK2 (PAK3 is not expressed in skeletal muscle) are activated 
in response to insulin [69,87,107] and are suggested to mediate Rac1-dependent insulin-stimulated 
reorganization of the actin cytoskeleton and GLUT4 translocation in skeletal muscle cells [108]. 
However, the role of group I PAKs in mature mouse skeletal muscle is debated. One study reported 
markedly impaired insulin-stimulated GLUT4 translocation in vivo in skeletal muscle lacking PAK1 
[69], while recent work in our laboratory found no impairment in insulin-stimulated glucose uptake 
in PAK1 knockout mouse skeletal muscle in vivo or in isolated muscles in vitro [109]. In transgenic 
mice jointly lacking PAK1 and PAK2 only a mild reduction in insulin-stimulated glucose transport 
in muscle was evident [109], suggesting that group I PAKs play only a minor role in the regulation of 
glucose uptake. In support of this, constitutively activated Cdc42, an activator of group I PAKs, did 
not stimulate GLUT4 translocation in muscle cells in vitro [90]. The discrepancy between the PAK 
studies could perhaps be explained by the age of the mice, as double PAK1/2 knockout mice exhibit 
other age-related phenotypes [110]. Further downstream of Rac1, signaling through Arp2/3 and 
cofilin could mediate the cortical actin polymerization evoked by insulin (see Figure 2). In L6 
myoblasts siRNA-mediated silencing of Arp3 abrogates actin remodeling and impairs GLUT4 
translocation [47]. Moreover, cofilin knockdown causes overwhelming actin polymerization that 
subsequently inhibits GLUT4 translocation [47]. Those findings suggest that most distal regulators 
of actin cytoskeleton dynamics evoked by Rac1 are involved in insulin-stimulated glucose uptake, 
although those findings remain to be confirmed in differentiated muscle and in vivo. Thus, while the 
important role for Rac1 in insulin-stimulated glucose uptake is clear, Rac1 likely mediates glucose 
uptake via PAK-dependent, but also PAK-independent mechanisms that remain to be elucidated. 
An input by RhoA in the regulation of insulin-stimulated glucose transport, has also been 
proposed, although the results are few and rather inconsistent [111]. Furthermore, all results are 
obtained by manipulating pathways downstream of RhoA and in several cases using 
pharmacological inhibitors reported to have unspecific effects [112]. Among the various effectors of 
RhoA, the kinase ROCK stands out. Two isoforms, ROCK1 and ROCK2, are expressed in skeletal 
muscle. ROCK1-deficient mice are insulin resistant [113] and siRNA-mediated silencing of ROCK1 
reduced insulin-stimulated glucose transport in L6 myotubes [114], suggesting that ROCK1 is a 
positive regulator of insulin signaling. In addition, overexpression of a dominant negative ROCK2 
or pharmacological inhibition of ROCKs impair insulin-stimulated GLUT4 translocation and glucose 
uptake in muscle in vivo [85]. 
Challenging a positive input of RhoA in the regulation of glucose uptake, membrane-bound 
(active) RhoA is elevated in skeletal muscles of obese Zucker rats [115]. In that model, jointly 
overexpressing a dominant-negative ROCK1 and 2 rescued diet-induced obesity and improved 
glucose tolerance [116], which contrasts with the findings in mice expressing only the dominant 
negative ROCK2 [85] or lacking ROCK1 [113] as described above. Interestingly, knockout of 
geranylgeranyl diphosphate synthase 1 (GGPPS; a branch point enzyme in the mevalonic acid 
pathway) specifically in skeletal muscle of mice decreased membrane-associated and prenylated 
RhoA (= active) and improved whole body glucose tolerance [117]. However, GGPPS might also 
affect the activity of other GTPases regulated by prenylations, including Rac1, which was not 
investigated. Thus, direct evidence for RhoA’s role in muscle insulin action is still lacking. 
Collectively, there is ample support that Rac1, and possibly RhoA, but seemingly not Cdc42, 
participate in the insulin-dependent regulation of glucose uptake in skeletal muscle. 
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2.2.2. Cross-Talk Between Rho GTPases and Canonical Insulin Signaling 
Canonical insulin signaling via Akt and TBC1D4 is a well-described signaling mechanism by 
which insulin increases muscle and adipose tissue glucose uptake [118,119]. In muscle and muscle 
cells in culture, both Akt/TBC1D4 and Rac1 are important regulators of insulin-stimulated glucose 
uptake. Studies from our laboratories have suggested that Rac1 and Akt mediate insulin-stimulated 
glucose uptake via parallel signaling mechanisms. This is because, in our hands, silencing Rac1 
expression via siRNA [89] or knocking out the Rac1 gene [87] did not affect insulin-stimulated Akt 
phosphorylation although it abolished GLUT4 translocation [83,86,90]. Moreover, by inhibiting Rac1 
or Akt2 separately, each partially reduced insulin-stimulated glucose transport, while joint 
inhibition of both pathways nearly fully blocked it [91]. Thus, the Rac1 and Akt pathways seem to 
act on GLUT4 translocation through distinct downstream processes. On the other hand, studies from 
the Satoh group point to cross-talk or feedback loops between the Rac1 and the Akt signaling 
pathways. For example, basal (but not insulin-stimulated) Akt activity was required for 
constitutively active Rac1 to induce GLUT4 translocation in L6 myotubes [90]. In agreement, Rac1 
and PAK have been reported to be involved in the activation of Akt in various cell types [120,121] 
suggesting the possible existence of a feedback loop between Rac1 and Akt. Also, several 
publications from Satoh´s group suggest that Akt2 is involved in insulin-stimulated Rac1 activation 
leading to glucose uptake in muscle [101,122,123]. Most recently, this was proposed because 
knockdown of Akt2 by siRNA abolished Rac1 activation following intravenous administration of 
insulin or ectopic expression of a constitutively activated PI3K mutant in mouse muscle [124]. 
Similarly, we have observed reduced insulin-stimulated phosphorylation of PAKs in extensor 
digitorum longus, but not soleus muscle from Akt2 KO mice, although this was not observed in any 
of the muscles in response to pharmacological Akt inhibition using MK2206 [91]. Thus, currently the 
relative role of each pathway and how they interact to regulate insulin-stimulated glucose uptake is 
not fully understood. In our hands, a superactivation of Rac1 achieved by an acute overstimulation 
of the Rho GTPase lead to Akt phosphorylation, but the levels of Rac1 superactivation are far higher 
than those physiologically stimulated by insulin [125]. Based on these collective results we propose 
that, in muscle, the level of Rac1 activation achieved with insulin does not suffice to stimulate Akt2, 
however, it is possible to show a connection between these signals when Rac1 activation is 
supraphysiological. Moreover, while Akt might have some regulatory role over Rac1, Rac1 activity 
does not rely on Akt. Rac1 can be activated independent of Akt, since exercise and muscle 
contraction, which do not activate Akt, activate Rac1. 
2.2.3. Exercise Elicits Metabolic Benefits via Regulation of Rho GTPases 
It has been convincingly documented that regular exercise improves glycemic control and 
insulin action among healthy, as well as obese and type 2 diabetic subjects [126–129], and that this 
effect can be superior to those exerted by drugs or insulin therapy [130,131]. Physical activity causes 
a large increase in energy utilization [126,132,133]. Glucose is a major fuel source for the contracting 
muscles and glucose uptake acutely increases more than 50-fold during exercise [133]. Because 
glucose is taken up by the contracting muscles via insulin-independent mechanisms [134,135], it is 
effective in lowering blood glucose in insulin resistant subjects [136]. 
Rac1 is activated during exercise in mouse and human skeletal muscle [137] and Rac1 
muscle-specific knockout mice exhibit reduced exercise-stimulated glucose uptake in muscle 
[138,139]. Likewise, GLUT4 translocation in response to electrical pulse stimulation (which mimics, 
but does not recapitulate muscle contraction) is reduced by inhibition of Rac1 in C2C12 myotubes 
[140]. 
Very recent results shed light onto the downstream events by which Rac1 may induce glucose 
uptake during exercise. Henriquez-Olguin et al. showed that Rac1 is implicated in the increase in 
ROS-production that occurs during exercise in muscle [141]. As described for pancreatic β cells, Rac1 
is an integral part of the NOX2 complex in skeletal muscle. In skeletal muscle Rac1-mediated 
production of ROS contributes to increased glucose uptake in mouse skeletal muscle during exercise 
[141]. Because mice lacking PAK1 displayed normal contraction-stimulated glucose transport in 
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skeletal muscle [109], one can assume that Rac1 does not mediate contraction-stimulated glucose 
uptake via PAK1. Rac1 would then be available for activation, contributing to NOX2 activation. The 
resulting ROS production would in turn contribute to the stimulation of muscle glucose uptake [141] 
by an unknown mechanism. Thus, Rac1 helps remove glucose from the blood via insulin 
independent mechanisms. 
In addition to the acute stimulation of glucose uptake by a single bout of exercise, exercise 
training also induces remarkable skeletal muscle adaptations that benefit metabolic regulation, 
including the enhancement of insulin sensitivity (recently reviewed in [126]). Recent work has 
implicated RhoA in exercise-training adaptations, as seen by the increased expression of ROCK1, 
ROCK2, and RhoA in rat gastrocnemius muscle following short-term swimming exercise training 
[142]. Furthermore, ROCK1/2 inhibition by Y-27632 impaired the insulin sensitizing effect of exercise 
training [142]. Although non-specific effects of pharmacological inhibitors cannot be ruled out, that 
study suggests that the downstream effectors of RhoA and ROCK1/2 are involved in the metabolic 
benefits of exercise training. 
Interestingly, exercise results in phosphorylation of RhoGDIα on serine 34 in human skeletal 
muscle [143]. Whether RhoGDIα serine 34 phosphorylation in muscle destabilizes its interaction 
with Rho GTPases to permit their activation during exercise will be interesting to determine. 
In summary, exercise elicits metabolic benefits, several of which involve regulation of Rho 
GTPases. Future studies should delineate the mechanisms by which Rho GTPases may be 
influencing health with exercise and importantly if they can be explored pharmaceutically to harness 
some of the metabolic benefits of exercise in individuals that cannot adhere to an exercise program. 
2.3. A Possible Role for Rho GTPases in Adipose Tissue Glucose Uptake 
Although being mainly a fat storage tissue, adipose tissue is also essential for maintaining 
metabolic homeostasis and health. Especially in conditions of obesity, adipose tissue takes up a 
substantial amount of glucose following a meal, thereby significantly contributing to the clearance of 
glucose from the blood. Like in skeletal muscle, adipocyte glucose uptake relies on the translocation 
of GLUT4 to the plasma membrane for glucose to diffuse across the membrane lipid bilayer. Insulin 
activates TC10 [144,145], Cdc42 [146], Rac1 [147], and RhoA [148] in adipocytes but their 
involvement in adipose tissue glucose uptake is not clear. 
An early investigation showed that transfection of a constitutively-active RhoA increased 
GLUT4 translocation in response to insulin, while dominant-negative RhoA significantly decreased 
it in 3T3-L1 and rat adipocytes [149]. Another study using siRNA-mediated Cdc42 knockdown 
reported that Cdc42 could mediate insulin signaling to glucose transport in 3T3-L1 adipocytes [146]. 
3T3-L1 adipocytes seemingly respond normally to insulin after transfection of a dominant-negative 
or constitutively-active Rac1 [150]. However, Marcusohn et al. did not confirm that the mutants, 
transfected in the fibroblast stage of the culture, persisted in the adipocyte stage where 
insulin-stimulated glucose uptake was studied. Nevertheless, that study was supported by the 
finding that pharmacological Rac1 inhibition did not reduce insulin-stimulated glucose uptake in 
incubated fat pads from mice [87], although actual inhibition of Rac1-signaling was not confirmed in 
that study. Thus, despite methodological issues, the few studies to date suggest no role for Rac1 in 
insulin stimulated glucose uptake in adipocytes. 
The Rho GTPase TC10 also seems relevant for regulating insulin-stimulated glucose uptake in 
adipose tissue as depicted in Figure 3. Dominant-negative TC10 prevents actin reorganization 
[151,152], an event that is necessary for adipocytes to translocate GLUT4 to the membrane. 
Accordingly, dominant-negative TC10 inhibits adipocyte glucose uptake and GLUT4 translocation 
[144]. That study [144] also reported no effect on insulin-stimulated GLUT4 translocation and 
glucose uptake of transfecting constitutively-active, or dominant-negative RhoA or Cdc42 in 
adipocytes (although data was not shown), contrasting with the other studies described above 
[146,149]. 
Taken together, Rho GTPases could play roles in adipocyte glucose uptake by regulating 
GLUT4 vesicle dynamics. Indeed, the fusion of GLUT4 vesicles with the adipocyte membrane 
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requires dynamic insulin-induced actin polymerization, evincing the contribution of the actin 
cytoskeleton at different steps in the process of GLUT4 translocation [153]. However, the studies 
linking Rho GTPases to this event are few and the results conflicting with only TC10 consistently 
shown to regulate insulin-stimulated GLUT4 translocation in adipocytes. Importantly, mechanistic 
in vivo evidence is completely lacking and there is currently no human evidence in the literature. 
Thus, the involvement of Rho GTPases in adipose tissue function is largely unexplored and exciting 
discoveries lie ahead. 
2.2.3. Rho GTPases are Implicated in Insulin Resistance—A Key Contributor to Metabolic Disease 
In insulin resistant human subjects that are obese or have type 2 diabetes, insulin-stimulated 
glucose uptake by skeletal muscle is a primary site of dysfunction [79]. Due to their key role in 
skeletal muscle (and perhaps adipocyte) glucose uptake, Rho GTPases are relevant in metabolic 
diseases, including type 2 diabetes. Decreased skeletal muscle Rac1 signaling has been associated 
with insulin resistance in insulin resistant obese and type 2 diabetic human subjects [87], as well as in 
diabetic ob/ob mice and diet-induced obese insulin resistant rodents [91]. This has also been 
proposed by in vitro studies of muscle showing that ceramide-induced insulin resistance was 
associated with marked impairments in insulin-induced Rac1 activation [89]. However, in another in 
vitro model of insulin resistance, palmitate treatment did not impair Rac1 activity, although the 
phosphorylation of Rac1’s downstream target, PAK1 was reduced [154]. Interestingly, in a recent 
study from our laboratory, we observed that lack of Rac1 in muscles from diet-induced obese mice 
exacerbates insulin resistance [155], suggesting a relevance for Rac1 in counteracting metabolic 
dysfunctions. Those studies highlight the possibility that compromised Rac1 activity and/or 
downstream signaling contribute to the development of muscular insulin resistance. 
RhoA might also regulate glucose homeostasis, as pharmacological inhibition of RhoA’s target, 
ROCK, using Fasudil prevented high-fat diet-induced hypercholesterolemia and glucose intolerance 
in mice [156]. Furthermore, body weight, serum lipid levels, and glucose metabolism were improved 
in mice with whole body overexpression of a dominant-negative ROCK, compared with littermate 
control mice [116]. In muscle cells in vitro, palmitic acid-induced insulin resistance was associated 
with increased expression of ROCK1 [157]. However, that ROCK would negatively affect glucose 
homeostasis contradicts the fact that lean ROCK1-deficient mice are insulin resistant [113] and lean 
mice with overexpression of a dominant negative ROCK2 display impaired insulin-stimulated 
GLUT4 translocation and glucose uptake in muscle in vivo [85]. Indeed, the RhoA-ROCK pathway 
seems to be clinically relevant, since insulin-stimulated muscle ROCK1/2 activity was attenuated in 
obese and type 2 diabetic subjects during an euglycemic hyperinsulinemic clamp compared to lean 
control [158]. Thus, the results on RhoA’s role in metabolic (dys)regulation warrant clarification. 
Taken together, Rho GTPases, in particular Rac1 and RhoA, may be highly implicated in 
muscular insulin resistance and thereby contribute to metabolic dysregulation in metabolic diseases, 
such as type 2 diabetes. 
3.1. Rho GTPases as Hitherto Unrecognized Regulators of Muscle Mass 
Muscle mass is important for metabolic health because it increases the amount of tissue 
available for storing glucose. Although studies are few, there is emerging evidence that Rho 
GTPases may play hitherto unrecognized roles in muscle mass regulation. Indeed, Rho GTPases are 
highly regulated during conditions of muscle atrophy. For example, a marked reduction in levels of 
RhoA was noted in the muscles of unweighted hindlimbs (an experimental model simulating 
muscle atrophy under weightlessness) in mice [159] and in dystrophic mice [160] along with rapid 
atrophy. In male Sprague-Dawley rats, three days of hindlimb suspension-induced muscle atrophy 
decreased RhoA mRNA and protein expression [161]. In contrast, muscle mass loss caused by 
denervation, increased RhoA expression but returned to baseline when the decline in muscle mass 
ceased [162]. Thus, RhoA expression is highly regulated in models of muscle mass loss although this 
remains to be recapitulated in human skeletal muscle [163]. Conversely, increasing muscle mass 
using functional overload and anabolic steroid administration in mice [164], or 
Cells 2019, 8, 434 12 of 21 
 
hypertrophy-stimulating resistance training in humans elevated the expression of skeletal muscle 
RhoA [165]. Future studies should investigate muscle mass regulation in muscles that lack RhoA in 
order to directly determine the implications for RhoA. 
Rho GTPases other than RhoA may also be involved in muscle mass regulation as proteomic 
analysis of mouse muscles following denervation-induced atrophy identified significant changes in 
RhoGDIα, PAK1-2, and Cdc42 expression [166]. Dominant-negative Cdc42, introduced with a 
retroviral vector, resulted in fibers that appeared atrophic [167] and blocking Rac1 function in 
precursors of the indirect flight muscle of Drosophila severely disrupted muscle formation. Thus, 
Rac1 is involved in the regulation of myoblast proliferation and segregation during adult 
myogenesis [168]. Downstream of Rac1 and Cdc42, PAK1 and PAK2 are activated during 
mammalian myoblast differentiation. Combined deletion of PAK1 and PAK2 results in reduced 
muscle mass, a phenotype that is exacerbated after repair to acute injury [110,169]. In support of that, 
pharmacological inhibition of group I PAKs (with IPA-3) delays skeletal muscle regeneration 
following cardiotoxin injury in vivo [170], suggesting that Rho GTPase-mediated signaling is 
important for muscle regeneration. Interestingly, insulin-stimulated phosphorylation of PAK1 at 
threonine 423 [171] and PAK1 protein content [171,172] were markedly increased in 
follistatin-induced hypertrophic mouse muscle compared to controls. 
A role for Rho GTPases in muscle mass regulation is perhaps not surprising given their 
well-known requirement for tumor growth. Looking ahead, lessons from the tumor literature may 
help to understand the mechanisms by which Rho GTPases may be involved in muscle mass 
regulation in connection with metabolic regulation. 
3.2. The Role of Rho GTPases in Muscle Wasting Conditions 
Skeletal muscle atrophy is a severe consequence of ageing and many chronic diseases, 
including cancers. Muscle strength is inversely related to death from all causes [173] and is of the 
utmost importance for the preservation of mobility and quality of life. RhoA and RhoGDIα are both 
upregulated in mouse skeletal muscle with age-related muscle mass loss [174]. In agreement, single 
muscle fiber proteomics analysis showed that RhoGDIα protein expression increased with age in 
both slow and fast muscle fibers from human biopsy samples, while RhoA increased with age 
predominantly in fast muscle fibers [175]. Importantly, age-related muscle atrophy only occurred in 
the fast muscle fiber types. However, contradicting those two studies, a recent study found reduced 
RhoA protein expression in skeletal muscle of middle-aged rats together with diminished levels of 
ROCK proteins [176]. Thus, Rho GTPases might be differentially regulated at different ages and 
stages of sarcopenia, and this warrants further investigation. 
Many cancers are associated with cachexia, a condition of involuntary body weight loss 
including severe muscle atrophy that is not due to anorexia [177]. Interestingly, PAK1 mRNA and 
protein expression are reduced in cancer-associated cachectic muscles from colon adenocarcinoma 
C26-bearing mice [170], although PAKs’ upstream Rho GTPases, Rac1, and Cdc42 were not 
examined. That is consistent with the role of group I PAKs in muscle mass regulation [110,169]. 
Indeed, PAK1 overexpression partly preserved fiber size in cachectic muscles [170], suggesting that 
the defect in PAK might be directly involved in the pathogenesis. From these collective studies, 
RhoA, Rac1 and Cdc42, and PAK emerge as candidate regulators of muscle mass. However, studies 
exploring a direct mechanistic role for the Rho GTPases in muscle mass regulation are completely 
lacking. 
As muscle is the largest organ of the body, completely necessary for mobility and also 
responsible for the majority of glucose disposal, future studies should investigate the role for Rho 
GTPases in muscle wasting diseases. 
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Box 1. Unresolved issues. 
Unresolved Issues 
• Lack of in vivo experiments to support the in vitro literature on Rho GTPase regulation 
and in particular their role in metabolism. 
• Evidence on the regulatory functions of Rho GTPases in humans is limited. 
• Molecularly, the upstream activators and downstream effectors of Rho GTPases in 
different tissues and in response to different stimuli are poorly defined. 
• Cross-talk between Rho GTPases is poorly defined but important to delineate, as they 
challenge all interpretation of data using knockdown or overexpression of a single Rho GTPase. 
• High throughput methodological advances to directly measure in vivo GTP binding 
(fast hydrolysis) warranted. 
• Whether Rho GTPases can be targeted pharmacologically to benefit metabolic diseases 
remains to be determined. 
4. Conclusion 
In this review, we summarize evidence for the role of Rho GTPases in metabolic regulation in 
health and disease. We demonstrate that Rho GTPases may be hitherto overlooked players in 
glucose homeostasis by contributing to metabolically essential functions in skeletal muscle, adipose 
tissue, and the pancreas. However, this area of research is at its early stages and mechanistic in vivo 
insights are lacking. This will be an exciting area for future discoveries. 
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